Comparative Evaluation of Anti-HER2 Affibody Molecules Labeled with 64Cu Using NOTA and NODAGA.
作者： Vladimir Tolmachev , Cheng-Bin Yim , Johan Rajander , Anna Perols , Amelie Eriksson Karlström
DOI: 10.1155/2017/8565802
关键词:
摘要: Imaging using affi body molecules enables discrimination between breast cancer metastases with high and low expression of HER2, making appropriate therapy selection possible. This study aimed to ev ...
hindawi.com
core.ac.uk参考文章(49)
Rodrigo Vazquez-Lombardi, Tri Giang Phan, Carsten Zimmermann, David Lowe, Lutz Jermutus, Daniel Christ, Challenges and opportunities for non-antibody scaffold drugs. Drug Discovery Today. ,vol. 20, pp. 1271- 1283 ,(2015) , 10.1016/J.DRUDIS.2015.09.004
Joachim Feldwisch, Vladimir Tolmachev, Engineering of affibody molecules for therapy and diagnostics. Methods of Molecular Biology. ,vol. 899, pp. 103- 126 ,(2012) , 10.1007/978-1-61779-921-1_7
Laura K. van Dijk, Cheng-Bin Yim, Gerben M. Franssen, Johannes H. A. M. Kaanders, Johan Rajander, Olof Solin, Tove J. Grönroos, Otto C. Boerman, Johan Bussink, PET of EGFR with (64) Cu-cetuximab-F(ab')2 in mice with head and neck squamous cell carcinoma xenografts. Contrast Media & Molecular Imaging. ,vol. 11, pp. 65- 70 ,(2016) , 10.1002/CMMI.1659
Eric W. Price, Chris Orvig, Matching chelators to radiometals for radiopharmaceuticals. Chemical Society Reviews. ,vol. 43, pp. 260- 290 ,(2014) , 10.1039/C3CS60304K
Viki-Veikko Elomaa, Jori Jurttila, Johan Rajander, Olof Solin, Automation of (64)Cu production at Turku PET Centre. Applied Radiation and Isotopes. ,vol. 89, pp. 74- 78 ,(2014) , 10.1016/J.APRADISO.2014.02.010
Michael Bilous, Patrick Fitzgibbons, Wedad Hanna, Robert B. Jenkins, Pamela B. Mangu, Soonmyung Paik, Edith A. Perez, Michael F. Press, Patricia A. Spears, Gail H. Vance, Giuseppe Viale, Daniel F. Hayes, Antonio C. Wolff, M. Elizabeth H. Hammond, David G. Hicks, Mitch Dowsett, Lisa M. McShane, Kimberly H. Allison, Donald C. Allred, John M.S. Bartlett, Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Archives of Pathology & Laboratory Medicine. ,vol. 138, pp. 241- 256 ,(2014) , 10.5858/ARPA.2013-0953-SA
Helena Wållberg, Anna Orlova, Slow Internalization of Anti-HER2 Synthetic Affibody Monomer 111In-DOTA-ZHER2:342-pep2 : Implications for Development of Labeled Tracers Cancer Biotherapy and Radiopharmaceuticals. ,vol. 23, pp. 435- 442 ,(2008) , 10.1089/CBR.2008.0464
Volkan Beylergil, Patrick G. Morris, Peter M. Smith-Jones, Shanu Modi, David Solit, Clifford A. Hudis, Yang Lu, Joseph O’Donoghue, Serge K. Lyashchenko, Jorge A. Carrasquillo, Steven M. Larson, Timothy J. Akhurst, Pilot study of 68Ga-DOTA-F(ab')2-trastuzumab in patients with breast cancer. Nuclear Medicine Communications. ,vol. 34, pp. 1157- 1165 ,(2013) , 10.1097/MNM.0B013E328365D99B
Thaddeus J Wadas, Carolyn J Anderson, Radiolabeling of TETA- and CB-TE2A-conjugated peptides with copper-64. Nature Protocols. ,vol. 1, pp. 3062- 3068 ,(2006) , 10.1038/NPROT.2006.431
Carlos L. Arteaga, Mark X. Sliwkowski, C. Kent Osborne, Edith A. Perez, Fabio Puglisi, Luca Gianni, Treatment of HER2-positive breast cancer: current status and future perspectives Nature Reviews Clinical Oncology. ,vol. 9, pp. 16- 32 ,(2012) , 10.1038/NRCLINONC.2011.177